Contradictions in Financial Guidance: Examining Market Growth, Tariffs, and Procedure Volumes in Recent Earnings Calls

Revenue and Procedural Growth:
- PROCEPT BioRobotics reported total revenue of $79.2 million for Q2 2025, representing 48% growth compared to Q2 2024.
- This growth was driven by U.S. revenue increasing to $69.6 million, a 46% year-over-year rise, and handpiece and other consumable revenue reaching $43.1 million, up 58% from the previous year.
- The rise in revenue was attributed to strong procedure volumes and increased surgeon adoption.

System Placements and ASPs:
- The company sold 48 new HYDROS robotic systems and replacement systems in Q2, with an average selling price of approximately $455,000.
- Despite a slight reduction in projected U.S. system revenue from $95 million to $93.5 million, the average selling price for greenfield systems has increased to $440,000 for the third and fourth quarters.
- The focus on greenfield placements and higher ASPs is aimed at capitalizing on significant expansion opportunities in the U.S. hospital market.

International Sales Expansion:
- International revenue for Q2 2025 was $9.6 million, representing 69% growth compared to the prior year.
- Growth was primarily driven by strong sales momentum in the United Kingdom, Japan, and Korea, contributing approximately 70% of all international sales.
- This expansion is part of the company's strategy to enhance global market penetration and increase sales outside the U.S.

Gross Margin and Cost Management:
- Gross margin for Q2 2025 increased to 65.4%, up 640 basis points year-over-year.
- This improvement was driven by increased operational efficiencies and higher average selling prices, indicating effective cost management strategies.
- The company's focus on operational improvements and revenue leverage has contributed to increasing profitability.